Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

Figure 1 Sensitivity of several non-small cell lung cancer cell lines to cisplatin (A) and crizotinib (B) monotherapy. Cells were exposed to the drugs for 72 h. Cisplatin and crizotinib concentrations are depicted in μmol/L. Values are means of at least 3 separate experiments. The maximal SEM was ± 9%.